Search results
Results from the WOW.Com Content Network
Metreleptin, sold under the brand name Myalept among others, is a synthetic analog of the hormone leptin used to treat various forms of dyslipidemia.It has been approved in Japan for metabolic disorders including lipodystrophy and in the United States as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired ...
Acquired generalized lipodystrophy (AGL), also known as Lawrence syndrome[ 1 ] and Lawrence–Seip syndrome, [ 1 ] is a rare skin condition that appears during childhood or adolescence, characterized by fat loss affecting large areas of the body, particularly the face, arms, and legs. [ 2 ]: 496 There are four types of lipodystrophy based on ...
Lipodystrophy can appear as a lump or small dent in the skin that forms when a person performs injections repeatedly in the same spot. These types of lipodystrophies are harmless and can be avoided by changing (rotating) the locations of injections. For those with diabetes, using purified insulins and new needles with each injection may also help.
U.S. FDA Grants Priority Review to Bristol-Myers Squibb and AstraZeneca's Metreleptin, an Investigational Agent for Treatment of Metabolic Disorders Associated with Rare Forms of Lipodystrophy ...
Leptin. Not to be confused with Lectin, Lecithin, or Lepton. Leptin (from Greek λεπτός leptos, "thin" or "light" or "small"), also known as obese protein, [ 6 ] is a protein hormone predominantly made by adipocytes (cells of adipose tissue). Its primary role is likely to regulate long-term energy balance. [ 7 ]
Congenital generalized lipodystrophy (CGL) is a rare autosomal recessive disorder which manifests with insulin resistance, absence of subcutaneous fat and muscular hypertrophy. [ 5 ] Homozygous or compound heterozygous mutations in four genes are associated with the four subtypes of CGL. [ 3 ] The condition appears in early childhood with ...
On February 4, 2014, the U.S. FDA approved Myalept (metreleptin), an analog of human leptin, [24] as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired generalized lipodystrophy. [25] Metraleptin was originally developed at Amylin Pharmaceuticals. [26]
Barraquer–Simons syndrome. Barraquer–Simons syndrome is a rare form of lipodystrophy, which usually first affects the head, and then spreads to the thorax. [2][3] It is named for Luis Barraquer Roviralta (1855–1928), a Spanish physician, and Arthur Simons (1879–1942), a German physician. [4][5][6] Some evidence links it to LMNB2. [7]